The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation

Introduction

The U.S. pharmaceutical market is at a critical inflection point in early 2026. For decades, the industry has operated within a framework that, while fostering significant innovation, has also resulted in the highest prescription drug prices in the world.

This long-standing paradox of balancing innovation with affordability is now being directly challenged by a confluence of sweeping legislative reforms, aggressive executive actions, and evolving market pressures. A perfect storm of policy changes, most notably the Inflation Reduction Act (IRA) of 2022 and the launch of the TrumpRx platform, is fundamentally reshaping the pricing and access landscape.

For industry professionals, navigating this unfamiliar environment requires a deep understanding of these disruptive forces and a proactive adaptation of long-held business strategies. This article analyzes the systemic barriers that have historically sustained high drug prices, examines the impact of recent policy interventions, and outlines critical strategic pathways for pharmaceutical leaders to consider as they steer their organizations through this period of unprecedented change.

The Enduring Challenge: Deconstructing Market-Entry Barriers

The high cost of medicine in the United States is not a new phenomenon, but its root causes are complex and deeply embedded in the nation’s legal and regulatory architecture. The story of insulin—a drug discovered in 1923—serves as a stark example.

In 2023, Americans faced costs of over $300 per vial for a medicine available for approximately $4.50 in India—a disparity that highlights how policy, not production cost, dictates price.¹ The core of the issue lies in a series of intertwined mechanisms that delay the market entry of affordable generic and biosimilar competitors long after a drug’s initial innovation has been rewarded.

Three primary mechanisms have been instrumental in creating and sustaining these barriers:

1. Patent Linkage and Cascading Delays

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, created a system of “patent linkage” that ties the FDA approval process directly to a drug’s patent status. When a generic manufacturer challenges a patent’s validity, the FDA is required to automatically halt the approval process for 30 months, giving the brand-name manufacturer time to litigate.

This provision, intended as a safeguard, has frequently been used as a tool to delay competition, regardless of the underlying patent’s merit.¹

2. Overlapping Regulatory Exclusivities

Independent of patents, the FDA grants various forms of market exclusivity that further extend monopoly periods. These include five years of data exclusivity for new chemical entities, three years for new clinical investigations, a six-month pediatric extension, and seven years for orphan drugs targeting rare diseases.

These exclusivities can be “stacked,” creating a formidable wall that prevents generic competition even for products that are combinations of older, off-patent drugs.¹

3. Evergreening and Patent Thickets

Perhaps the most controversial strategy is “evergreening,” in which manufacturers file numerous secondary patents on minor variations of a drug—such as new formulations, dosages, or methods of administration—to extend its monopoly life. This practice leads to the creation of “patent thickets,” dense webs of intellectual property that are prohibitively expensive and complex for competitors to challenge.

AbbVie’s Humira, for example, was protected by a thicket of over one hundred patents, which successfully delayed U.S. biosimilar competition for years after its primary patent expired, allowing it to generate over $114 billion in revenue for AbbVie since the end of 2016.² Similarly, Sanofi’s insulin product, Lantus, is associated with seventy-four patents that collectively protect it from competition for 37 years.¹

The Policy Response: A Two-Pronged Assault on High Prices

After years of public outcry and political debate, two significant federal initiatives have begun to dismantle this pricing structure.

The Inflation Reduction Act (IRA)

Enacted in 2022, the IRA granted Medicare the authority to directly negotiate the prices of high-cost prescription drugs for the first time. The program’s impact is unfolding in phases:

• First Negotiation Cycle (Effective 2026): The first ten drugs subject to negotiation, including blockbusters such as Eliquis, Jardiance, and Januvia, saw prices reduced by an average of 38%-60% below their 2023 list prices. These negotiated prices took effect on January 1, 2026.³
• Expanded Selection: The program is set to expand, with an additional fifteen drugs selected for negotiation for 2027, and a third cycle of drugs announced in January 2026 for prices effective in 2028. However, the 2025 budget reconciliation bill (H.R. 1) placed limitations on the scope of future negotiations, reducing projected savings.⁴

Despite its landmark status, the IRA has a critical limitation: it cannot address the high launch prices of new drugs, which are exempt from negotiation for their first nine years on the market. This has incentivized manufacturers to set aggressive initial prices to maximize revenue before negotiation becomes a factor.¹

Executive Action: TrumpRx and Most-Favored-Nation (MFN) Pricing

A more recent and arguably more disruptive development has been the Trump Administration’s executive actions. Stemming from a May 2025 Executive Order, this initiative aims to align U.S. drug prices with the lowest prices paid by other developed nations.

On February 5, 2026, the administration launched TrumpRx.gov, a direct-to-consumer platform offering MFN pricing on dozens of popular medicines. The initial launch included five major manufacturers: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. The price reductions are significant, particularly for the highly sought-after GLP-1 agonists used for diabetes and weight loss.⁵

• Ozempic and Wegovy (injectable): Monthly prices reduced from over $1,000 to an average of $350.
• Zepbound (injectable): Monthly price reduced from over $1,000 to an average of $346.
• Wegovy (oral): Monthly price as low as $149.

This platform moves from a complex reimbursement system to a more transparent, cash-pay model and directly confronting the global price disparities that have long subsidized lower prices abroad at the expense of American patients.

Strategic Pathways for a New Reality

The cumulative impact of the IRA and MFN pricing demands a fundamental re-evaluation of pharmaceutical strategy. Resistance to this new reality is likely to invite even more stringent regulatory controls.

The most sustainable path forward involves accepting price negotiation as a permanent feature of the market and adapting business models accordingly.

Immediate Priorities (2026-2027):

• Embrace Price Transparency: The success of TrumpRx signals a move toward direct-to-consumer engagement. Companies must develop strategies to communicate value directly to patients in a transparent pricing environment.
• Re-evaluate Patent Strategy: With increased scrutiny from the USPTO on patent quality and legislative proposals targeting patent thickets, the era of relying on evergreening for lifecycle management is ending. The focus must shift from filing dozens of secondary patents to protecting genuinely novel inventions.
• Prepare for Broader Negotiations: Companies with drugs likely to be selected in future IRA negotiation cycles must begin developing their value propositions and pricing strategies now.

Long-Term Strategic Shifts:

• Prioritize True Innovation: The market will no longer reward minor, incremental improvements with extended monopolies. R&D investment must be directed toward first-in-class therapies and significant therapeutic advances that can justify their prices based on clinical value, not just patent protection.
• Engage Constructively in Policy: The industry must move from a defensive posture to one of constructive engagement. By participating in discussions about value-based pricing and sustainable innovation, manufacturers can help shape future policies rather than simply reacting to it.

Conclusion

The American pharmaceutical landscape of 2026 is fundamentally different from that of just a few years ago. The twin pressures of Medicare negotiation and MFN pricing have broken a decade-long cycle of price inflation and delayed competition.

The insulin narrative—innovative in 1923, unaffordable in 2023, and finally becoming affordable in 2026—demonstrates that a balance between innovation and access is not only possible but is now becoming a policy-driven reality. Industry leaders who recognize this shift and pivot their strategies from defending the old system to thriving in the new one will be best positioned for success, ensuring both continued innovation and the long-term sustainability of the pharmaceutical sector.

References

1. Ragavan, S. (2024). Make America Healthy: Reducing High Pharmaceutical Prices Without Reducing Innovation. SMU Law Review, 77(4), 787-838.
2. Robbins, R. (2023, January 28). How a Drug Company Made $114 Billion by Gaming the U.S. Patent System. The New York Times.
3. Centers for Medicare & Medicaid Services. (2026). Medicare Drug Price Negotiation Program Fact Sheet. Retrieved from CMS.gov.
4. Good News! Medicare’s Negotiated Drug Prices for ten of the Most… (2026, January 30). California Health Advocates.
5. The White House. (2026, February 5). Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients. Retrieved from Whitehouse.gov.

Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.

About the Author

Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He is currently SVP, Life Sciences, at Coforge Limited, a $1.7B multinational digital solutions and technology consulting services company. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC. Mr. Anbil has consulted with and counseled Health and Life Sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He was a member of the IBM Industry Academy, a highly selective group of professionals inducted by invitation only, the highest honor at IBM. He is a healthcare expert member of the World Economic Forum (WEF). He is also a Life Sciences industry advisor at MIT, his alma mater.